Countervail Awarded $225,000 SBIR Phase I Grant For Diagnostic Test Development February 6, 2018 • Bill Basinger • Agriculture, Diagnostic Tests, Funding, Grants Read More »
Preclinical Toxicology Study Shows Excellent Results On Countervail’s Lead Antidote Candidate January 2, 2018 • admin • Funding, General News, Grants, Pharmaceuticals Read More »
Countervail Corporation’s Pre-proposal Accepted by NINDS CounterACT October 7, 2016 • admin • Grants, Pharmaceuticals Read More »
Countervail Corporation presents significant results of orally dosed AverTox (galantamine) for improved survival from exposure to lethal levels of soman at the CounterACT Symposium held at the New York Academy of Sciences. June 17, 2015 • admin • Funding, Grants Read More »
Countervail receives $981,000 SBIR Fast Track Phase II grant award for continued development of AverTox® (galantamine) for pre-exposure administration to protect against soman toxicity. December 7, 2013 • admin • Funding, Grants Read More »
Countervail Corporation Awarded Additional $343,000 SBIR Phase II Grant for Continued Development of Medical Countermeasure to Nerve Agents September 9, 2013 • admin • Funding, Grants Read More »
Countervail corporation is awarded $346,000 for phase 1 of fast track SBIR Grant from the National Institutes of Health for studies of nerve gas antidote September 12, 2010 • admin • Grants, Military Read More »
